GeNeuro SA announces the opening of receivership proceedings for its French subsidiary GeNeuro Innovation SAS
Geneva, Switzerland, 12 June 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that, at the company’s request, the Lyon Economic Activities Court decided on June 11, 2025 to open receivership proceedings against GeNeuro Innovation SAS, the sole subsidiary of […]
GeNeuro SA Announces an Extraordinary Shareholders’ Meeting on June 30, 2025
Geneva, Switzerland, 10 June 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an extraordinary shareholders’ meeting on June 30, 2025. As previously disclosed, GeNeuro is subject to a definitive debt-restructuring moratorium granted by the Geneva […]
GeNeuro SA Announces Definitive Debt-Restructuring Moratorium
Geneva, Switzerland, 27 May 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has, in a May 26, 2025, judgment, granted GeNeuro SA a four-month definitive debt-restructuring moratorium, under the continued supervision of […]
GeNeuro SA announces the postponement of the publication of the Company’s 2024 annual results
Geneva, Switzerland, 12 May 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of the publication of its December 31, 2024 annual results and annual financial report in order to be able to take into account the financial […]
GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium
Geneva, Switzerland, 28 January 2025 – 6:00 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has renewed the provisional debt-restructuring moratorium granted to the Company in September 2024. The moratorium has been extended for an […]
Detecting HERV-K ENV and neutralizing induced neurotoxicity in sporadic ALS: a rationale for precision medicine
New data supporting a new precision medicine approach for ALS patients with GeNeuro’s GNK-301 presented at the 35th International Symposium on ALS/MND
Geneva, Switzerland, December 6, 2024 – 6:30 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as amyotrophic lateral sclerosis (ALS), today announced that groundbreaking findings on a potential precision medicine strategy for ALS with GeNeuro’s GNK-301 were […]
GeNeuro SA obtains the opening of debt-restructuring proceedings
Geneva, Switzerland, 30 September 2024 – 7:00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – G NRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has approved its application for a debt-restructuring moratorium dated July 15, 2024, aimed at restructuring its debts and finding […]
New data presented at the ECTRIMS 2024 Congress in Copenhagen shows that Temelimab rescues the neurodegenerative effects of HERV-W in an MS model
Geneva, Switzerland, September 19, 2024 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that new findings on the anti-neurodegenerative effect of Temelimab in an MS model were presented as […]
GeNeuro announces that it submits a request for a debt moratorium to the Geneva Court of First Instance
Geneva, Switzerland, July 15, 2024 – 7:00 am CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or COVID-Long), announces that it will submit today to the […]